vs
Side-by-side financial comparison of FREQUENCY ELECTRONICS INC (FEIM) and Intellia Therapeutics, Inc. (NTLA). Click either name above to swap in a different company.
Intellia Therapeutics, Inc. is the larger business by last-quarter revenue ($23.0M vs $17.1M, roughly 1.3× FREQUENCY ELECTRONICS INC). FREQUENCY ELECTRONICS INC runs the higher net margin — 10.5% vs -416.2%, a 426.7% gap on every dollar of revenue. On growth, Intellia Therapeutics, Inc. posted the faster year-over-year revenue change (78.8% vs 8.3%). FREQUENCY ELECTRONICS INC produced more free cash flow last quarter ($-1.1M vs $-69.4M). Over the past eight quarters, FREQUENCY ELECTRONICS INC's revenue compounded faster (11.8% CAGR vs -10.8%).
Ultra Electronics Holdings is a British defence and security company. It was listed on the London Stock Exchange and was a constituent of the FTSE 250 Index until it was acquired by Cobham, which is itself owned by Advent International.
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineere...
FEIM vs NTLA — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $17.1M | $23.0M |
| Net Profit | $1.8M | $-95.8M |
| Gross Margin | 38.2% | — |
| Operating Margin | 10.0% | -428.9% |
| Net Margin | 10.5% | -416.2% |
| Revenue YoY | 8.3% | 78.8% |
| Net Profit YoY | -32.1% | 25.7% |
| EPS (diluted) | $0.18 | $-0.81 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $17.1M | $23.0M | ||
| Q3 25 | $13.8M | $13.8M | ||
| Q2 25 | $20.0M | $14.2M | ||
| Q1 25 | $18.9M | $16.6M | ||
| Q4 24 | $15.8M | $12.9M | ||
| Q3 24 | $15.1M | $9.1M | ||
| Q2 24 | $15.6M | $7.0M | ||
| Q1 24 | $13.7M | $28.9M |
| Q4 25 | $1.8M | $-95.8M | ||
| Q3 25 | $634.0K | $-101.3M | ||
| Q2 25 | $3.2M | $-101.3M | ||
| Q1 25 | $15.4M | $-114.3M | ||
| Q4 24 | $2.7M | $-128.9M | ||
| Q3 24 | $2.4M | $-135.7M | ||
| Q2 24 | $2.6M | $-147.0M | ||
| Q1 24 | $130.0K | $-107.4M |
| Q4 25 | 38.2% | — | ||
| Q3 25 | 36.8% | — | ||
| Q2 25 | 37.5% | — | ||
| Q1 25 | 43.8% | — | ||
| Q4 24 | 48.2% | — | ||
| Q3 24 | 44.4% | — | ||
| Q2 24 | 40.3% | — | ||
| Q1 24 | 22.6% | — |
| Q4 25 | 10.0% | -428.9% | ||
| Q3 25 | 2.6% | -808.9% | ||
| Q2 25 | 16.4% | -772.2% | ||
| Q1 25 | 18.3% | -726.6% | ||
| Q4 24 | 16.5% | -1059.9% | ||
| Q3 24 | 15.7% | -1589.0% | ||
| Q2 24 | 16.0% | -1998.6% | ||
| Q1 24 | -3.4% | -394.0% |
| Q4 25 | 10.5% | -416.2% | ||
| Q3 25 | 4.6% | -735.2% | ||
| Q2 25 | 16.0% | -710.8% | ||
| Q1 25 | 81.4% | -687.6% | ||
| Q4 24 | 16.8% | -1001.2% | ||
| Q3 24 | 16.1% | -1489.5% | ||
| Q2 24 | 16.9% | -2112.6% | ||
| Q1 24 | 0.9% | -371.3% |
| Q4 25 | $0.18 | $-0.81 | ||
| Q3 25 | $0.07 | $-0.92 | ||
| Q2 25 | $0.33 | $-0.98 | ||
| Q1 25 | $1.60 | $-1.10 | ||
| Q4 24 | $0.28 | $-1.27 | ||
| Q3 24 | $0.25 | $-1.34 | ||
| Q2 24 | $0.28 | $-1.52 | ||
| Q1 24 | $0.01 | $-1.12 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $3.0M | $449.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $58.5M | $671.4M |
| Total Assets | $92.3M | $842.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $3.0M | $449.9M | ||
| Q3 25 | $4.5M | $511.0M | ||
| Q2 25 | $4.7M | $459.7M | ||
| Q1 25 | $5.5M | $503.7M | ||
| Q4 24 | $9.7M | $601.5M | ||
| Q3 24 | $16.2M | $658.1M | ||
| Q2 24 | $18.3M | $691.1M | ||
| Q1 24 | $11.7M | $791.3M |
| Q4 25 | $58.5M | $671.4M | ||
| Q3 25 | $56.3M | $748.4M | ||
| Q2 25 | $55.6M | $715.3M | ||
| Q1 25 | $51.8M | $779.9M | ||
| Q4 24 | $36.2M | $872.0M | ||
| Q3 24 | $33.2M | $962.6M | ||
| Q2 24 | $39.8M | $971.1M | ||
| Q1 24 | $36.7M | $1.0B |
| Q4 25 | $92.3M | $842.1M | ||
| Q3 25 | $93.2M | $925.3M | ||
| Q2 25 | $93.7M | $898.9M | ||
| Q1 25 | $86.4M | $986.2M | ||
| Q4 24 | $77.8M | $1.2B | ||
| Q3 24 | $84.3M | $1.2B | ||
| Q2 24 | $83.3M | $1.2B | ||
| Q1 24 | $77.7M | $1.3B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-523.0K | $-69.3M |
| Free Cash FlowOCF − Capex | $-1.1M | $-69.4M |
| FCF MarginFCF / Revenue | -6.6% | -301.6% |
| Capex IntensityCapex / Revenue | 3.6% | 0.5% |
| Cash ConversionOCF / Net Profit | -0.29× | — |
| TTM Free Cash FlowTrailing 4 quarters | $-5.5M | $-395.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-523.0K | $-69.3M | ||
| Q3 25 | $1.2M | $-76.9M | ||
| Q2 25 | $-155.0K | $-99.6M | ||
| Q1 25 | $-3.6M | $-148.9M | ||
| Q4 24 | $3.8M | $-85.2M | ||
| Q3 24 | $-1.5M | $-84.8M | ||
| Q2 24 | $7.5M | $-58.2M | ||
| Q1 24 | $4.2M | $-120.7M |
| Q4 25 | $-1.1M | $-69.4M | ||
| Q3 25 | $385.0K | $-76.9M | ||
| Q2 25 | $-786.0K | $-99.9M | ||
| Q1 25 | $-4.0M | $-149.7M | ||
| Q4 24 | $3.3M | $-86.2M | ||
| Q3 24 | $-1.8M | $-86.1M | ||
| Q2 24 | $6.7M | $-59.2M | ||
| Q1 24 | $3.9M | $-123.2M |
| Q4 25 | -6.6% | -301.6% | ||
| Q3 25 | 2.8% | -558.2% | ||
| Q2 25 | -3.9% | -701.0% | ||
| Q1 25 | -20.9% | -900.1% | ||
| Q4 24 | 20.8% | -669.4% | ||
| Q3 24 | -11.8% | -945.2% | ||
| Q2 24 | 42.8% | -850.9% | ||
| Q1 24 | 28.4% | -425.7% |
| Q4 25 | 3.6% | 0.5% | ||
| Q3 25 | 5.6% | 0.2% | ||
| Q2 25 | 3.2% | 1.7% | ||
| Q1 25 | 1.7% | 4.4% | ||
| Q4 24 | 3.3% | 7.6% | ||
| Q3 24 | 2.2% | 14.0% | ||
| Q2 24 | 5.3% | 14.5% | ||
| Q1 24 | 2.3% | 8.7% |
| Q4 25 | -0.29× | — | ||
| Q3 25 | 1.83× | — | ||
| Q2 25 | -0.05× | — | ||
| Q1 25 | -0.24× | — | ||
| Q4 24 | 1.44× | — | ||
| Q3 24 | -0.60× | — | ||
| Q2 24 | 2.85× | — | ||
| Q1 24 | 32.36× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FEIM
| POC Revenue | $14.8M | 86% |
| POT Revenue | $2.3M | 13% |
NTLA
| Avencell Therapeutics Inc | $21.0M | 91% |
| Other | $1.0M | 4% |
| Avencell | $1.0M | 4% |
